Brief: Rallybio Initiates Dosing In RLYB116 Phase 1 Confirmatory Study
12/06/2025 13:20
June 12 (Reuters) - Rallybio Corp RLYB.O: RALLYBIO INITIATES DOSING IN RLYB116 PHASE 1 CONFIRMATORY PHARMACOKINETIC/PHARMACODYNAMIC STUDY RALLYBIO CORP - DATA READOUTS EXPECTED FROM COHORT 1 IN 3Q 2025 AND COHORT 2 IN 4Q 2025 Source text: ID:nBw5dVb64a Further company coverage: RLYB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rallybio
See all newsNASDAQ RESUMED AT 08:48 AM
Brief: Rallybio Corporation And Avenzo Therapeutics Announce Merger Agreement To Advance Next-Generation Oncology Therapies And $215 Million Concurrent Private Placement
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
U.S. STOCKS ON THE MOVE-Mirum Pharma
U.S. STOCKS ON THE MOVE-Mirum Pharma, eBay, FedEx